Roivant and Priovant Secure FDA Approval for First Targeted Oral Therapy for Dermatomyositis

As reported on Pharma Phorum, Roivant Sciences and its subsidiary Priovant Therapeutics have received U.S. Food and Drug Administration (FDA) approval for Lisraya (brepocitinib), marking the first targeted treatment specifically…

Continue Reading Roivant and Priovant Secure FDA Approval for First Targeted Oral Therapy for Dermatomyositis